Generic Horizant Availability
Last updated on Apr 10, 2025.
Horizant is a brand name of gabapentin enacarbil, approved by the FDA in the following formulation(s):
HORIZANT (gabapentin enacarbil - tablet, extended release;oral)
-
Manufacturer: AZURITY
Approval date: April 6, 2011
Strength(s): 600MG [RLD] -
Manufacturer: AZURITY
Approval date: December 13, 2011
Strength(s): 300MG [RLD]
Is there a generic version of Horizant available?
No. There is currently no therapeutically equivalent version of Horizant available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Horizant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Prodrugs of GABA analogs, compositions and uses thereof
Patent 6,818,787
Issued: November 16, 2004
Inventor(s): Gallop; Mark A. et al.
Assignee(s): Xenoport, Inc. (Santa Clara, CA)The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
Patent expiration dates:
- April 6, 2025✓✓
- April 6, 2025
-
Crystalline form of .gamma.-aminobutyric acid analog
Patent 8,026,279
Issued: September 27, 2011
Inventor(s): Estrada; Tono et al.
Assignee(s): XenoPort, Inc. (Santa Clara, CA)A crystalline form of a .gamma.-aminobutyric acid analog, and methods of preparing same, are provided.
Patent expiration dates:
- November 10, 2026✓✓
- November 10, 2026
-
Treating or preventing restless legs syndrome using prodrugs of GABA analogs
Patent 8,114,909
Issued: February 14, 2012
Inventor(s): Barrett Ronald W. & Canafax Daniel M.
Assignee(s): XenoPort, Inc.Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.
Patent expiration dates:
- April 11, 2026✓
- April 11, 2026
-
Crystalline form of γ-aminobutyric acid analog
Patent 8,686,034
Issued: April 1, 2014
Inventor(s): Estrada Tono & Raillard Stephen P. & Frauenfelder Christine & Zacher Uwe
Assignee(s): XenoPort, Inc.A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided.
Patent expiration dates:
- January 24, 2025✓
- January 24, 2025✓
- January 24, 2025
-
GABA analog prodrug sustained release oral dosage forms
Patent 8,795,725
Issued: August 5, 2014
Inventor(s): Cundy Kenneth C. & Sastry Srikonda & Leung Manshiu & Kadri Balaji V. & Stach Paul E.
Assignee(s): XenoPort, Inc.Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
Patent expiration dates:
- June 10, 2029✓✓
- June 10, 2029✓✓
- June 10, 2029
More about Horizant (gabapentin enacarbil)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (37)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: gamma-aminobutyric acid analogs
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
